Xin Lang Cai Jing·2025-12-26 02:26Core Viewpoint - Spring Medical has shown significant growth in revenue and net profit, indicating strong performance in the orthopedic medical device sector, particularly in implantable products [2][3]. Group 1: Financial Performance - For the period from January to September 2025, Spring Medical achieved operating revenue of 756 million yuan, representing a year-on-year growth of 48.75% [2]. - The net profit attributable to the parent company for the same period was 192 million yuan, reflecting a substantial year-on-year increase of 213.21% [2]. - Cumulative cash dividends since the company's A-share listing amount to 359 million yuan, with 309 million yuan distributed over the past three years [3]. Group 2: Shareholder and Market Activity - As of December 25, 2025, Spring Medical's financing balance was 34.05 million yuan, accounting for 0.49% of its market capitalization, which is above the 50th percentile level over the past year [1]. - The company had a total of 6,164 shareholders as of September 30, 2025, an increase of 4.12% from the previous period [2]. - Notable institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed Fund A, both of which are new entrants among the top ten circulating shareholders [3]. Group 3: Product and Business Overview - Spring Medical specializes in the research, development, production, and sales of implantable orthopedic medical devices, with a primary focus on joint prosthetics and spinal implants [2]. - The company's product offerings include a full range of spinal fixation systems and joint prosthetics for the hip, knee, shoulder, and elbow [2]. - The majority of the company's revenue, 99.89%, comes from medical device products, with a small fraction (0.11%) from other sources [2].